Lifecare Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Lifecare'in kazancının yıllık 7.9% oranında azalması, yıllık gelirinin ise yıllık 14.3% oranında artması beklenmektedir. EPS'nin yılda 0.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -140.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

-7.9%

Kazanç büyüme oranı

0.5%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	18.8%
Gelir büyüme oranı	14.3%
Gelecekteki özkaynak getirisi	-140.9%
Analist kapsamı	Low
Son güncelleme	15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

We Think Lifecare (OB:LIFE) Can Afford To Drive Business Growth

Sep 13

We're Interested To See How Lifecare (OB:LIFE) Uses Its Cash Hoard To Grow

Apr 30

Kazanç ve Gelir Büyüme Tahminleri

OB:LIFE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (NOK Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	15	-74	-77	-64	2
12/31/2025	6	-74	-74	-62	2
12/31/2024	N/A	-71	-88	-72	1
9/30/2024	15	-58	-64	-51	N/A
6/30/2024	16	-50	-46	-40	N/A
3/31/2024	11	-42	-41	-41	N/A
12/31/2023	13	-35	-37	-36	N/A
9/30/2023	13	-34	-40	-40	N/A
6/30/2023	17	-27	-34	-33	N/A
3/31/2023	23	-21	-28	-27	N/A
12/31/2022	22	-17	-24	-18	N/A
9/30/2022	17	-13	N/A	N/A	N/A
6/30/2022	10	-17	-28	-16	N/A
3/31/2022	4	-18	-25	-13	N/A
12/31/2021	2	-16	-21	-14	N/A
9/30/2021	N/A	-10	N/A	N/A	N/A
6/30/2021	5	-6	N/A	N/A	N/A
3/31/2021	5	-4	N/A	N/A	N/A
12/31/2020	5	-3	-3	-3	N/A
9/30/2020	0	-5	N/A	N/A	N/A
6/30/2020	0	-6	N/A	N/A	N/A
3/31/2020	0	-6	N/A	N/A	N/A
12/31/2019	N/A	-7	-7	-7	N/A
9/30/2019	0	-8	N/A	N/A	N/A
6/30/2019	0	-10	N/A	N/A	N/A
3/31/2019	0	-9	N/A	N/A	N/A
12/31/2018	N/A	-9	N/A	N/A	N/A
9/30/2018	0	-6	N/A	N/A	N/A
6/30/2018	0	-3	N/A	N/A	N/A
3/31/2018	0	-3	N/A	N/A	N/A
12/31/2017	N/A	-3	N/A	N/A	N/A
12/31/2016	N/A	-5	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: LIFE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: LIFE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: LIFE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: LIFE şirketinin gelirinin (yıllık 14.3% ) Norwegian pazarından (yıllık 2.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: LIFE şirketinin gelirinin (yıllık 14.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: LIFE 3 yıl içinde kârsız olması bekleniyor.

Lifecare Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 13% to kr31.00

Price target decreased by 8.0% to kr34.50

Price target decreased by 31% to kr37.50

Price target decreased by 20% to kr47.00

Recent updates

Price target decreased by 13% to kr31.00

Third quarter 2024 earnings released: kr1.07 loss per share (vs kr0.78 loss in 3Q 2023)

Price target decreased by 8.0% to kr34.50

Lifecare AS to Report Q1, 2025 Results on May 15, 2025

Lifecare AS to Report Fiscal Year 2024 Results on Mar 28, 2025

Price target decreased by 31% to kr37.50

Lifecare ASA Announces Biopsies and Bacteriological Existing Implant

Lifecare AS has filed a Follow-on Equity Offering in the amount of NOK 20 million.

Price target decreased by 20% to kr47.00

New major risk - Market cap size

Lifecare AS (OB:LIFE) commences an Equity Buyback Plan, under the authorization approved on September 17, 2024.

We Think Lifecare (OB:LIFE) Can Afford To Drive Business Growth

Lifecare AS Announces Successful Completion of the First Veterinary Patient of the Life Life Trial

New major risk - Shareholder dilution

Lifecare AS has completed a Follow-on Equity Offering in the amount of NOK 90 million.

Lifecare AS Files Application for a New Patent

Lifecare AS Announces Successful Pilot Production

Lifecare AS has filed a Follow-on Equity Offering in the amount of NOK 90 million.

Full year 2023 earnings released: kr0.29 loss per share (vs kr0.17 loss in FY 2022)

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.15 loss in FY 2022)

Lifecare AS Appoints Renete Kaarvik as Chief Financial Officer, Effective 1 Mai 2024

Lifecare AS Announces Appointment of Tony James to Its Scientific Advisory Board

Lifecare AS, Annual General Meeting, Apr 30, 2024

New minor risk - Shareholder dilution

Lifecare AS Announces the Norwegian Food Safety Authority Receives Approval to Start LFC-SEN-002

Lifecare AS has completed a Follow-on Equity Offering in the amount of NOK 42.5 million.

New major risk - Financial position

Lifecare AS to Report Q1, 2023 Results on May 10, 2023

No independent directors

Lifecare AS Announces Interim Data Analysis of the First In-Human Study

Lifecare as Initiates Clinical Studies of the Smallest Glucose Sensor in the Worldr People Diagnosed with Diabeabetes

Chief Executive Officer recently bought kr75k worth of stock

No independent directors

Lifecare AS (OB:LIFE) signed a term sheet agreement to acquire PFÜTZNER Science & Health Institute GmbH for €1.18 million.

Lifecare AS (OB:LIFE) acquired Cantimed Ug (Haftungsbeschrsnkt) from NanoScale Systems Gmbh for €0.65 million.

Chairman of the Board Christian Hysing-Dahl has left the company

We're Interested To See How Lifecare (OB:LIFE) Uses Its Cash Hoard To Grow

Lifecare AS to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day high: kr6.40

New 90-day low: kr3.62

Lifecare AS Announces Board Appointments

New 90-day low: kr4.00

Lifecare Receives EUR 3.9 Million from the EU Commission for Development of Bionic Invisible Pancreas to Forgetdiabetes

New 90-day high: kr7.00

Chief Scientific Officer recently sold kr270k worth of stock

Lifecare Appoints Joacim Holter as CEO

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin